The role of miR-24 as a race related genetic factor in prostate cancer. by Hashimoto, Yutaka et al.
UCSF
UC San Francisco Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
Oncotarget16581www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 10), pp: 16581-16593
The role of miR-24 as a race related genetic factor in prostate 
cancer
Yutaka Hashimoto1,*, Marisa Shiina1,*, Taku Kato1, Soichiro Yamamura1, Yuichiro 
Tanaka1, Shahana Majid1, Sharanjot Saini1, Varahram Shahryari1, Priyanka 
Kulkarni1, Pritha Dasgupta1, Yozo Mitsui1, Mitsuho Sumida1, Guoren Deng1, Laura 
Tabatabai2, Deepak Kumar3, Rajvir Dahiya1
1Department of Urology, VA Medical Center and UCSF, San Francisco, CA 94121, USA
2Department of Pathology, Veterans Affairs Medical Center and University of California at San Francisco, San Francisco, CA 
94121, USA
3Julius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), Department of Pharmaceutical Sciences, North 
Carolina Central University, Durham, NC 27707, USA
*These authors contributed equally to this work
Correspondence to: Rajvir Dahiya, email: Rdahiya@ucsf.edu
Keywords: race related prostate cancer, miRNA, pathway modulation, DNA methylation
Received: December 01, 2016    Accepted: January 24, 2017    Published: February 02, 2017
ABSTRACT
The incidence of prostate cancer (PCa) among African-Americans (AfA) is 
significantly higher than Caucasian-Americans (CaA) but the genetic basis for this 
disparity is not known. To address this problem, we analyzed miRNA expression in AfA 
(n = 81) and CaA (n = 51) PCa patients. Here, we found that miR-24 is differentially 
expressed in AfA and CaA PCa patients and attempt to clarify its role in AfA patients. 
Also, the public sequencing data of the miR-24 promoter confirmed that it was highly 
methylated and down-regulated in PCa patients. Utilizing a VAMCSF and NDRI patient 
cohorts, we discovered that miR-24 expression was linked to a racial difference between 
AfA/CaA PCa patients. Interestingly, miR-24 was restored after treatment of PCa cells 
with 5Aza-CdR in an AfA cell line (MDA-PCa-2b), while restoration of miR-24 was not 
observed in CaA cells, DU-145. Ectopic expression of miR-24 showed decreased growth 
and induced apoptosis, though the effect was less in the CaA cell line compared to the 
AfA cell line. Finally, we found unique changes in biological pathways and processes 
associated with miR-24 transfected AfA cells by quantitative PCR-based gene expression 
array. Evaluation of the altered pathways showed that AR, IGF1, IGFBP5 and ETV1 
were markedly decreased in the AfA derived cell line compared with CaA cells, and 
there was a reciprocal regulatory relationship of miR-24/target expression in prostate 
cancer patients. These results demonstrate that miR-24 may be a central regulator 
of key events that contribute to race-related tumorigenesis and has potential to be a 
therapeutic agent for PCa treatment.
INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed 
type of cancer among men in the US, accounting for 30% of 
new cancers. While the rate of PCa has declined, African-
Americans (AfA) have the world’s highest incidence of 
PCa with more than two-fold greater mortality compared 
with Caucasian Americans (CaA) (NIH; SEER Stat Fact 
Sheets). Overall, AfA PCa patients are earlier age and have 
higher Gleason scores, PSA levels, and incidence of palpable 
disease [1, 2]. Multiple factors have been correlated with 
aggressive prostate tumors. For instance, differential cancer-
related gene expression in AfA patients contributes to higher 
grade tumor [3, 4], and epigenetic mechanisms, such as 
DNA methylation, effects genes regulation [5]. These reports 
indicate that AfA patients have hyper-methylation of genes 
in normal or pre-cancerous prostate tissues that may promote 
malignancy. Thus hyper-methylation of tumor-suppressor 
genes may be involved in the racial differences between 
AfA and CaA patients [6, 7]. However, the relationship 
between these abnormal methylation patterns and prostate 
carcinogenesis is still unknown.
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MicroRNAs (miRNAs) are small non-coding RNA 
which consists of 19–23 nucleotides and regulate various 
genes chiefly through mRNA target degradation and 
translational repression. It has been reported that more than 
60% of human protein-coding are regulated by miRNAs [8]. 
Numerous published reports show that miRNA expression 
levels are related to cancer progression and patient prognosis. 
Recently, DNA methylation of CpG islands in miRNA 
promoters has been shown to limit miRNA expression 
in various human cancers, including PCa [9, 10]. miRNA 
expression profiles show differences between healthy tissues 
and cancers [11]and also during tumor progression [12]. 
Nevertheless, miRNA expression as a race-related factor in 
PCa has not been fully investigated. Hence, a major topic 
is whether African-American men have a higher overall 
incidence, earlier age of onset, increased clinically advanced 
disease and increased bone metastases and mortality from 
prostate cancer due to differentially expressed miRNAs 
compared to Caucasians. Among the differentially expressed 
miRNAs, miR-24 is reported to be a tumor suppressor 
miRNA in prostate cancer [13–16], however its functional 
role in PCa comparing AfA and CaA has not been examined.
Here, we have examined whether dysregulated 
miR-24, may help in understanding the genetic basis 
for prostate cancer health disparities. In this study, we 
correlate miR-24 expression in AfA and CaA PCa cohorts 
and show that miR-24 down-regulation in an AfA PCa 
cell line has a dramatic effects on several pathways as 
compared to CaA cell line.
RESULTS
Down-regulation of miR-24 is significantly 
correlated with race in AfA and CaA prostate 
cancer patients
Initially, we confirmed miR-24 expression levels 
in prostate cancer patients using the The Cancer Genome 
Atlas (TCGA) and Gene Expression Omnibus (GEO) 
(GSE21036, Taylor et al.) databases. In agreement with 
previously published reports, miR-24 was significantly 
down-regulated in PCa samples compared with normal 
tissues (Figure 1B) in the both of TCGA and Taylor cohorts. 
However, the TCGA cohort includes very few AfA samples 
(n = 7) and Taylor cohort does not have racial information. 
We then analyzed a VAMCSF and NDRI cohorts consisting 
of 81 AfA and 51 CaA samples and found that miR-24 
levels were significantly correlated with race using Fisher’s 
exact test (p = 0.0318, OR = 8.562693, 95% CI [0.985, 
76.77]) (Figure 1C and Supplementary Table 2).
5Aza-CdR restores expression of miR-24 in 
MDA-PCa-2b
Since total miR-24 expression levels were lower 
in MDA-PCa-2b cells compared with DU-145 cells 
(Supplementary Figure 1) and the miR-24-1 promoter was 
hyper-methylated in PCa patients from the TCGA database 
(Figure 1A and 1D), we looked to see if reduced miR-24 
levels in MDA-PCa-2b cells was due to DNA promoter 
hyper-methylation. We observed that the expression level of 
miR-24 was increased after 72 hours treatment with 5Aza-
CdR in MDA-PCa-2b but not in DU-145 cells (Figure 1E).
miR-24 over-expression affected on the cell 
viability of AfA PC cell line MDA-PCa-2b more 
than that of CaA cell line DU-145
To understand race-related functional differences 
of miR-24, we performed cell viability assays after 
transfection with miR-24 mimic. miR-24 over-expression 
decreased cell proliferation in both MDA-PCa-2b and DU-
145 cells compared with negative controls. Importantly, 
reduced cell viability by miR-24 was more pronounced 
in MDA-PCa-2b cells (p = 0.008) than DU-145 cells 
(p = 0.05) (Figure 2A and 2B).
Different mechanisms regulate apoptosis in 
MDA-PCA-2b and DU-145 cell lines
Apoptosis was quantified using Annexin V staining 
after transfection of miR-24. miR-24 increased (> 11.3-
fold) apoptosis in MDA-PCa-2b cells compared to negative 
control at day six after transfection, while DU-145 cells 
showed a 3-fold increase of apoptosis at day four (Figure 3A 
and 3B). Up-regulation of cleaved Caspase-3 was 
observed in MDA-PCa-2b cells transfected with miR-24, 
however down-regulation of cleaved Caspse-3 was 
observed in DU-145 cells (Supplementary Figure 2). Thus 
AfA and CaA cells apparently have distinct mechanisms for 
regulation of apoptosis.
We also checked the cell cycle status of DU-145 and 
MDA-PCa-2b cell lines after transfection with miR-24. 
The G2/M phase of the cell cycle was slightly increased 
in DU-145(Controls 18.3% vs Transfected cells 28.3%, 
p = 0.02), while transfected MDA-PCa-2b cells showed no 
differences in cell cycle distribution compared to negative 
control (Figure 3C and 3D).
miR-24 increases expression tumor suppressor 
genes
To determine which biological pathways are 
involved in race-related PCa, we did RT2 qPCR-based 
array profiling using an assay with PCa related genes and 
compared gene expression profiles in the AfA and CaA 
cell lines. The results showed different expression levels 
of several genes related to apoptosis (ETV1, GNRH1, 
PTEN, TIMP2, IGF1 and BCL2) in MDA-PCa-2b and 
DU-145 cells (Figure 4A and Supplementary Figure 3).  
As mentioned in Materials & Methods, we 
calculated gene expression log fold-changes to help further 
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define race-related PCa pathways. miR-24 decreased all 
apoptosis (ETV1, IGF1, BCL2 and CASP3) and cell cycle 
related genes (IGF1, PTGS1, BCL2, CASP3 and APC) 
(logFC ≤ –0.415) that were up-regulated in MDA-PCa-
2b as compared to DU-145 (log(dMDA/DU) ≥ 0.585) 
(Supplementary Figure 3). Indeed, our apoptosis analyses 
with FACS corresponded to the qPCR array results 
(Figure 3A). On another note, two (AR and IGF1) out of 
three genes in the Androgen Receptor (AR) pathway that 
were up-regulated in MDA-PCa-2b cells (log(dMDA/DU) 
≥ 0.585) showed specific down-regulation after miR-24 
transfection (logFC ≤ –0.415) (Supplementary Figure 3). 
Remarkably, expression of 8 out of 18 genes that assigned 
in hyper-methylated in PCa was recovered especially in 
Figure 1: Chromosome location of miR-24-1 and expression levels in PCa tissues. (A) Schematic diagram of miR-24-1 on 
chromosome 9 from UCSC genome browser. (B) Box plot of miR-24 expression using TCGA (Normal, n = 67; PCa, n = 480) and GEO 
(Normal, n = 28; PCa, n = 113) databases. (C) Quantitative PCR expression analysis with AfA and CaA prostate cancer tissues from 
VAMCSF and NDRI patient cohorts (CaA, n = 51; AfA, n = 81). Cut off; Z = 2, Fisher’s exact test, p = 0.03181, OR = 8.562693, 95% CI 
[0.9850, 76.77]. (D) Heatmap and box plot showing methylation level of TCGA 450K array data (Normal, n = 49; PCa, n = 506). P-value 
was calculated by Mann-Whitney U test. Bar = ± SD. (E) miR-24 expression level in 5Aza-CdR treated and untreated PCa cell lines. 
P-value was calculated by two-tailed t-test. Bar = ± SEM.
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MDA-PCa-2b after miR-24 transfection (Supplementary 
Figure 3). Genes in the Transcription Factor, and PI3K/
AKT pathways were also up-regulated in MDA-PCa-2b 
and decreased by miR-24 over-expression (4 out of 7 
and 3 out of 5, respectively) (Supplementary Figure 3), 
while miR-24 has not decreased these genes in DU-145. 
Interestingly, Fatty Acid Metabolism pathway related genes 
were also down-regulated in MDA-PCa-2b after miR-24 
transfection.  These results show that these three pathways 
were more activated in MDA-PCa-2b cells compared 
to DU-145 and may be important for understanding the 
role of genetic factors in race related prostate cancer 
(Supplementary Figure 3, Figure 4A and 4C).
miR-24 targets genes in multiple cancer-related 
pathways
In order to confirm whether the pathways that 
we mentioned above are statistically significant, we 
performed conventional pathway enrichment analysis with 
ConcensusPathDB (CPDB). Using CPDB analysis also 
detected that the Prostate Cancer, and IGF Signaling Pathway 
were suppressed at the mRNA level in miR-24 transfected 
MDA-PCa-2b cells compared with controls (p = 5.87E-11 
and p = 1.17E-04) (Supplementary Table 3), while there were 
no reductions in expression in DU-145 cells.  In addition 
to these three pathways, genes that were down-regulated 
only in MDA-PCa-2b cells by miR-24 transfection, were 
significantly enriched in the PI3K-Akt and AR Signaling 
Pathways (p = 2.79E-05 and p = 8.73E-05) (Supplementary 
Table 3) in agreement with the results of our calculations.
To evaluate whether miR-24 caused the reduction 
of these genes directly or indirectly, we collated the 
down-regulated genes with a miRNA target prediction 
database “miRWalk”. We looked at the potential targets 
of miR-24 that were annotated in at least one of the four 
databases (TargetScan, RNA22, miRanda and Pictar) using 
miRWalk. In total, 10114 genes were registered in the four 
databases without overlaps. The nine genes (indicated 
by blue empty boxes) annotated as miR-24 targets and 
down-regulated in both DU-145 and MDA-PCa-2b 
are shown in Figure 4B (log(dDU) ≤ –0.415 and log(dMDA) 
Figure 2: miR-24 over-expression decreases PCa cell proliferation. (A, B) Left bar graphs, Relative expression level of miR-24 
after transfection with miR-24 mimic and negative control; Right line plots, Proliferation assay of MDA-PCa2b, DU-145 and cells that 
were transfected with miR-24 mimic or negative control for 6 days. Bar = ± SEM.
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≤ –0.415). Five (CAMKK1, DDX11, FASN, GPX3 and 
KLHL) of those nine genes were decreased substantially 
in MDA-PCa-2b cells compared to DU-145 cells (logFC 
≤ –0.415).  We also have identified 13 genes (indicated 
by red empty boxes) which were repressed in MDA-PCa-
2b by miR-24, but not decreased in DU-145 (log(dDU) ≥ 
–0.415, log(dMDA) ≤ –0.415 and logFC ≤ –0.415). This 
group included several well-known oncogenic genes such 
as AR, ETV1, and IGF1. These genes are highlighted in the 
KEGG pathway map by R package “pathview” (Figure 4C 
and Supplementary Figure 4). Two genes shown in white 
boxes are also important as PCa biomarkers and in PCa 
cancer development. However down-regulation of KLK3 
and EGFR in MDA-PCa-2b were lesser than cut-off value 
(log(dMDA) ≥ –0.415) (Supplementary Figure 3).
miR-24 down-regulates the PCa related 
oncogenes
We then confirmed our qPCR array results by 
quantitative PCR. Eight genes were selected from the 13 genes 
which were particularly down-regulated in MDA-PCa-2b 
cells and PPP2R1b was used as a negative control. Significant 
down-regulation of 5 genes was confirmed by using qPCR. 
Of note, AR, IGF1, IGFBP5 and ETV1 expression were not 
been detected in DU-145 cells, while expression of both 
Figure 3: miR-24 over-expression and analyses of apoptosis and cell cycle. (A, B) The percentages of apoptosis in MDA-
PCa-2b and DU-145 cells were analyzed by flow cytometry after miR-24 mimic or negative control transfection. Results shown are 
representative of three independent experiments. Bar = ± SEM. (C, D) Cell cycle analyses of MDA-PCa-2b and DU-145 cells were carried 
out by flow cytometry after miR-24 mimic and negative control transfection. Bar = ± SEM.
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genes was dramatically reduced by miR-24 in MDA-PCa-2b 
cells (Figure 5A).  The decreased protein expression levels 
of AR, IGF1, ETV1, and one of VEGFA splicing variants 
(lower column) were observed in MDA-PCa-2b after miR-24 
over-expression (Figure 5B). To determine whether the 
predicted miR-24 binding sites of target genes would 
function for miRNA binding, we carried out Dual Luciferase 
Reporter Assay. We referred the miR-24 binding sequences by 
TargetScan and RNA22 (Supplementary Table 1) and carried 
out Dual luciferase reporter assay with the vectors containing 
miR-24 binding site. Two days after co-transfection each 
vector and miR-24, the relative luciferase activities of AR, 
IGF1 IGFBP5, and VEGFA binding site coding vectors 
significantly reduced compared to negative control transfected 
cells. However, other binding sites of AR and IGFBP5 were 
not significantly changed (Figure 5C).
In silico analysis with TCGA database indicated 
inverse relationships between miR-24-1 and target gene 
expressions (AR, IGF1, and VEGFA) in PCa tissues, 
respectively (Figure 5D).
Figure 4: Gene expression profile analyses evaluating the effect of miR-24 on prostate cancer cell lines by qPCR 
based array analysis. (A) Hierarchical clustering and heatmap analyses of gene expression profiles in DU-145 and MDA-PCa-2b. The 
expression values were calculated by dividing values of miR-24 transfectant with that of negative control. (B) Venn diagram of miR-24 
predicted targets and down-regulated genes after miR-24 transfection in MDA-PCa-2b and DU-145. Blue, circle indicates the group 
of genes which are predicted by at least one database out of miRWalk, TargetScan, miRanda and RNA22. The pink circle show down-
regulated genes (≤ 0.75 FC) in DU-145 cells. Yellow circle shows down-regulated genes (≤ 0.75 FC) in MDA-PCa-2b cells. Green shows 
genes that are down-regulated only in MDA-PCa-2b (≤ 0.75 FC), but did not in DU-145 cell. (C) Pathway map with representative genes 
altered by miR-24. “Pathview” analysis mapped qPCR array data to “Pathway in Prostate Cancer”, “Transcriptional Misregulation in 
Cancer” that has been defined by KEGG pathway database and renders pathway graph with the mapped data. The boxes surrounding gene 
symbols are illustrated by two colors. Left side color of the box shows expression change in DU-145 cells after miR-24 transfection and 
right side shows that for MDA-PCa-2b cells. The color indicates gene expression level in each cell line.
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AR expression levels reciprocally associated with 
miR-24 expression in AfA PCa tissues
To confirm whether miR-24 expression impact on 
AR expression level in AfA PCa patients. We performed 
immunochemical staining for 24 AfA (Figure 6A) and 
11 CaA PCa tissue slides and compared AR and miR-24 
relative expression levels by linear regression model 
(Figure 6B). The AR positive area in the PCa tissues 
shows reciprocally associated with miR-24 expression 
level in AfA PCa patients of VAMCSF cohort as well as 
CaA samples (Figure 6B). However, The AR positive area 
was larger in AfA samples compared to the CaA derived 
samples (Mann-whitney U test; p = 0.03).
DISCUSSION
A number of studies have shown differential gene 
expression patterns in AfA and CaA PCa (18–22). These 
reports suggest that those may be race-related genetic 
factors in PCa. However to date, identification of these 
genes has not been accomplished. We hypothesized that 
Figure 5: Predicted target gene expression changes after miR-24 induction. (A) qPCR analyses for the predicted target genes 
of miR-24. We checked candidate gene expression levels after miR-24 over-expression. *p < 0.05, Bar = ± SEM. (B) Western blotting 
of miR-24 target genes. (C)The results of Dual Luciferase Reporter Assays. Except for IGF1, all genes have two different binding sites 
(for instance; AR-1 and AR-2 mean that miR-24 was predicted that it may bind to two different site of AR mRNA). *p < 0.05, n.s; no 
significance, Bar = ± SEM. (D) Linear regression model of mRNA expression levels between miR-24-1 and its five target genes in human 
PCa samples.
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miRNAs may be key factors in abnormal gene regulation 
in AfA PCa patients. In this study, we have shown that 
miR-24 is a potent tumor suppressor in a AfA PCa cell line.
Previous studies of kidney cancer [23], 
gastrointestinal cancer [24], esophageal and bladder cancer 
[25, 26] including PCa [27] have shown that miRNA levels 
are decreased in tumors due to DNA promoter hyper-
methylation. Thus, we also analyzed the methylation 
status of miR-24-1 and -2. miR-24-1/ -2 are located on 
chromosomes 9 and 19, respectively. In silico analysis in 
TCGA database showed hyper-methylation of miR-24-1 
in PCa patients. Thus, we considered the possibility that 
miR-24 expression was decreased in AfA prostate cancer 
patients due to promoter hyper-methylation. In MDA-
PCa-2b cell lines, 5Aza-CdR treatment restored miR-24 
expression but not in DU-145 cells. This result further 
supported the idea that hyper-methylation of CpG islands 
may suppress miR-24-1 expression thereby generating a 
difference in miR-24 expression between the two races.
In this study, we identified several biological 
pathways that are related to prostate cancer that showed 
different alterations in the AfA cell line compared with the 
CaA derived cell line by CPDB analysis (Supplementary 
Table 3). These pathways are well-known as critical in the 
development or suppression of prostate cancer. miR-24 is 
involved in the regulation of these pathways, prohibiting 
cancer development in AfA cell lines.
According to published reports, some AfA PCa 
patients have higher serum PSA (tumor volume per unit 
of PSA adjusted for prostate weight) than CaA patients. 
Tangen et al. have reported that PSA-based screening 
for PCa could have benefit on the overall survival of 
AfA PCa patients with hormone sensitive and metastatic 
prostate cancer [28, 29].  Identification of AR pathway 
suppression by miR-24 (Figure 4C) may explain why AfA 
prostate cancer patients had higher PSA levels. Similarly, 
IGF1 and Akt signaling pathways were significantly 
reduced in the AfA derived cell line compared with the 
CaA cell line. Indeed, both pathways have been reported 
to be involved in AR regulation and established pathways 
that promote human prostate cancer [30–33] (Figure 4C). 
Besides a change in AR expression, the IGF signaling 
affects PI3/Akt pathway and activations of these two 
signaling pathways could contribute to PSA up-regulation 
in AfA patients. We have already reported that the 
activated Akt pathway and miR-34b dysregulation induces 
prostate cancer development and poor prognosis [9]. In 
AfA patients, dysregulations of miRNA mediated gene 
regulation may result in malignant PCa.
We detected restorations of tumor suppressor genes 
by miR-24. As analyzed by Western Blotting, miR-24 
decreased EZH2 and this alteration may cause histone 
methylation changes and restorations of hyper-methylated 
genes in cancer. In several PCa cell lines, EZH2 affects 
SFRP1 and IGFBP7 expression levels by histone and 
DNA methylation [34]. Further studies are needed to 
document the epigenetic changes induced by miR-24.
The race-related responses to the ectopic induction 
of miR-24 between AfA and CaA have not been reported 
previously. Therefore, we performed quantitative PCR-
based expression array analysis using MDA-PCa-2b and 
DU-145 cell lines. Some, 38.3% and 45% of the genes 
that were annotated in the array were down-regulated after 
ectopic expression of miR-24 in DU-145 and MDA-PCa-2b. 
Among them, about 50 % of the genes decreased by 
miR-24 transfection were annotated by miRWalk. These 
Figure 6: Analyses of AR protein expression in AfA PCa tissues. (A) Immunohistochemical staining of AR protein expression. 
The staining is representative of 24 AfA (Black-filled triangles) and 11 CaA (Grey-filled circles) PCa tissues. The number shown in the 
IHC image indicates the sample ID that is the same as shown in Figure 6B. (B) Association of AR expression positive area and miR-24 
expression level in AfA PCa and 11 CaA tissues.
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alterations prompted us to focus on conventional PCa 
related pathways that are regulated by miR-24 rather than 
individual genes.
miR-24 had a greater effect on cell proliferation and 
apoptosis in the AfA derived cell line compared to CaA 
cells. These differences may be attributed to the number 
of genes which were decreased by miR-24. Following our 
qPCR-based array, 39 genes identified as prostate cancer 
related were totally down-regulated in MDA-PCa-2b 
(Figure 4B and Supplementary Table 3). Furthermore, 23 
genes were decreased in the AfA cell line including AR, 
IGF1, IGFBP1, ETV1 and VEGF which are predicted as 
miR-24 oncogene targets in the database. In contrast, only 
17 genes were specifically decreased in DU-145 cells and 
13 of these 17 genes were identified as miR-24 targets 
in the database. Interestingly, IGF1, ETV1, IGFBP5 and 
AR expression levels were significantly lower in DU-145 
compared with MDA-PCa-2b. Thus, miR-24 decreased 
expression levels of these genes only in MDA-PCa-
2b cells. Also, AR and IGF1 have been reported to be 
genetically aberrant in AfA PCa patients and are possibly 
race-related genetic factors in PCa (35,36). In our results 
of IHC analyses, AR expression levels were significantly 
increased in AfA compared to CaA PCa patients (p = 0.03) 
and lower miR-24 expression levels were observed in the 
samples that showed higher AR expression (Figure 6A, 6B 
and Supplementary Figure 5). Hence it is possible that 
abnormal over-expression of race-related PCa oncogenes 
such as AR and IGF1 in AfA cells is accelerated by down-
regulation of miR-24. This result also indicates that the 
differences in basal AR and miR-24 expression levels 
in prostate cancer could be one of the reasons for racial 
disparity between AfA and CaA patients might rise. In 
this study, we chose AR-negative cell line, DU-145 and 
AR-positive cell line, MDA-PCA-2b. The comparison 
with these CaA and AfA cell line by qPCR array would 
be justified because AR expression levels in CaA were 
significantly lower than in AfA tissues. On the other hand, 
VEGFA was expressed in both CaA and AfA cell lines. 
Nevertheless, down-regulation of VEGFA expression was 
observed only in MDA-PCa-2b. Additional studies will be 
required to explain this difference.
Although 60% of human genes were predicted as 
target of miRNAs [8], miR-24 was also confirmed as 
a regulator of various gene in PCa. In addition to the 
reductions of target genes by miR-24 transfection, our 
linear regression analysis with TCGA database indicates 
inverse correlation between miR-24 and each three target 
genes (AR, IGF1 and VEGFA), and supports that miR-24 
may directly control these three oncogenes in human PCa 
(Figure 5B, 5C and 5D). 
In summary, this work has shown that the down-
regulation of miR-24 correlated with race difference. Also 
the dysregulation of tumor suppressor miR-24 results in 
low levels in an AfA derived cell line (MDA-PCa-2b), 
compared to a CaA cell line (DU-145). Due to the fact 
that a large number of cancer-related pathways were 
suppressed after miR-24 over-expression, miR-24 may be 
a central regulator of key events that contribute to race-
related tumorigenesis. Thus miR-24 may be a potential 
therapeutic candidate for PCa treatment. These results 
also provide further insight into the molecular mechanisms 
associated with aggressive PCa in AfA patients.
MATERIALS AND METHODS
Cell lines
Human Prostate cell lines MDA-PCa-2b, DU-145 
were obtained from the American Type Culture Collection 
(ATCC). Caucasian American (CaA) derived cell line, DU-
145 was maintained in RPMI-1640 medium and HPC1 
medium was used for the African American (AfA) derived 
cell line, MDA-PCa-2b. RPMI-1640 and HPC1 media 
were supplemented with 10% and 20% fetal bovine serum, 
respectively with 100 IU/mL penicillin and 100 μg/mL 
streptomycin. Cells were incubated at 37°C in humidified 
5% CO2. To facilitate MDA-PCa-2b attachment, Poly-L-
Lysine (Sigma–Aldrich) Cell Attachment Protocol was 
implemented for all cell culture plates and dishes. These 
human-derived cell lines were authenticated by DNA 
short-tandem repeat analysis by the ATCC.
Cell cycle analysis
Cells were harvested, washed and fixed in cold 70% 
ethanol overnight at –20˚C. Cell pellets were stained with 
PI/RNase Staining Buffer (BD Pharmingen) and incubated 
for 15 minutes at room temperature in the dark. Cells were 
analyzed for DNA content by gate excluding doublet cells 
on BD FACSVerse (BD Pharmingen). All analyses were 
performed in triplicate and 10,000 gated events/sample 
were counted.
Apoptosis assay
Cells were transfected with miRNAs or negative 
control and harvested at different time points. Cells were 
washed in cold PBS, resuspended in 1x binding buffer and 
stained with Annexin V-FITC and 7AAD viability dye 
(Annexin V-FITC/7AAD kit, Beckman Coulter). After 15 
minutes incubation at room temperature in the dark, cells 
were washed and analyzed using BD FACSVerse (BD 
Pharmingen).
Western blot analysis
Cells were with NP-40 (Thermo Scientific) plus 
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo 
Scientific). Protein concentration was measured using 
the BCA Protein Assay (Thermo). Western blots were 
performed using NuPAGE 4–12% Bis-Tris Protein Gels 
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(Invitrogen). For gel electrophoresis, the iBlot 2 Dry 
Blotting System (Invitrogen) was used with MES buffer 
(Invitrogen) and transferred onto nitrocellulose transfer 
membrane.  Membranes were incubated with Odyssey 
blocking buffer (Li-Cor) prior to incubation with primary 
antibodies overnight at 4°C. Goat anti-rabbit IgG (H+L) 
800 CW or goat anti-mouse (H+L) 680RD was applied 
for 45 minutes at room temperature (1:15000, LI-COR) 
before washing with PBS with Tween 20. An Odyssey 
Infrared Imaging System Scanner was used to generate 
immunoblot images and the LI-COR Odyssey scanner 
and software (LI-COR Biosciences) were utilized for 
band quantification. The antibodies used were specific for 
AR (5153; Cell Signaling; 1:2000), ETV1 (PA5-41484; 
ThermoFisher Scientific; 1:1000), IGF1 (PA5-27207; 
ThermoFisher Scientific; 1:1000), VEGF (PA5-16754; 
ThermoFisher Scientific; 1:200), and β-actin (3700; Cell 
Signaling; 1:2000). 
Measurement of cell viability
Cell proliferation was estimated by Victor X2 
(PerkinElmer) and Cell Titer Glo Luminescent Cell 
Viability Assays (Promega) were performed every 
24 hours for 6 days after transfection of the miR-24 mimics 
(Thermo Fisher Scientific) following the manufacturer’s 
instructions. mirVana miRNA Mimic Negative Control #1 
was transfected as a control (Thermo Fisher Scientific).
5Aza-CdR treatment of cells and RNA extraction
For demethylation study cells were treated daily with 
10 μmol/L 5-Aza-Deoxycitydine(5Aza-CdR) (Sigma–
Aldrich) for 72 hours. Total RNA was isolated using a 
miRNeasy mini kit (Qiagen).
In silico DNA methylation analysis
DNA hypermethylation of the miR-24-1 promoter 
region, was validated using TCGA data portal (https://
tcga-data.nci.nih.gov/tcga/). The analyzed samples 
included 49 normal and 506 prostate cancer samples. 
We obtained TCGA DNA methylation data from the 
HumanMethylation 450 BeadChip (level 3). 
Quantitative real-time reverse transcription–
polymerase chain reaction
Real-time reverse transcription–polymerase 
chain reaction (RT–PCR) was carried out using a Quant 
Studio 7 PCR System, TaqMan Universal PCR Master 
Mix, TaqMan Reverse Transcription kit and TaqMan 
miRNA assays (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. The expression levels of 
miRNA were determined on the amount of target miRNA 
relative to that of RNU48 as a control to normalize the 
initial input of total RNA. A QuantiFast SYBR Green PCR 
Kit was also utilized for gene expression analysis of miR-
24 targets. The primers used for SYBR Green-based qPCR 
analyses are listed in Supplementary Table 1.
Transfection with miRNA mimic
In order to induce miR-24 expression, cells were 
transfected with mirVana miRNA mimics (100nM) 
(Thermo Fisher Scientific) using Lipofectamine RNAi 
Max (Thermo Fisher Scientific). To verify the transfection 
effect of miRNA mimics, mirVana miRNA Mimic 
Negative Control #1 (100 nM) (Thermo Fisher Scientific) 
was included in each transfection experiment.
RT² profiler PCR array analysis
Expression profiling of 84 genes involved in 
prostate cancer was performed utilizing human RT² 
Profiler PCR Array PAHS-135Z (Qiagen) based on SYBR-
Green real-time PCR. Three biological replicates were 
prepared for each miRNA and control transfections and 
the isolated RNA samples from PC cell lines treated the 
same condition were pooled. cDNA was synthesized from 
2866 ng and 855 ng RNA per pool isolated from MDA-
PCa-2b and DU-145 respectively, using RT² First Strand 
Kit (Qiagen) following the manufacturer’s instructions. 
SYBR-Green real-time PCR was performed and fold-
change calculations were done using RT² Profiler PCR 
Array Data Analysis.
Pathway analysis
All expression data obtained from the results of 
the RT² Profiler PCR Array data was calculated as the 
logarithm of each gene expression value and processed 
by global median centering normalization. For pathway 
mapping, the R package “pathview” was utilized [17]. The 
pathway analysis was performed by Concensus PathDB 
(http://consensuspathdb.org). 
Identifying AfA specific oncogenic targets and 
pathways
To define AfA specific oncogenic targets and 
pathways of miR-24, we categorized genes according 
to gene function and calculated log fold-change. We 
first divided gene expression values of Control MDA-
PCa-2b with those of control DU-145 and calculated the 
logarithm, “log(dMDA/DU)” to compare the basal gene 
expression levels.  Then we calculated gene expression 
changes after miR-24 transfection in both cell lines by 
dividing gene expression values for miR-24 transfected 
cells with expression values of control transfectants 
took the logarithm and named them “log(dDU)” and 
“log(dMDA)”, respectively. Finally we obtained “logFC” 
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by subtracting “log(dMDA)” from “log(dDU)”. The lower 
“logFC” means that the gene was less expressed in MDA-
PCa-2b cells than DU-145 cells after miR-24 transfection. 
Dual luciferase reporter assay
The Luciferase reporter vectors were constructed 
by ligation with the annealed custom oligonucleotides 
containing the putative target binding sites of 3′-UTR 
into pmiR-GLO reporter vector (Promega, Madison, 
WI) (Supplementary Table 1). miR-24 transfected in 
HEK293T9 cells was co-transfected with 1 ng of the 
pmiR-GLO vector with the 3′-UTR sequences and 
luciferase activity was measured 48 hr after transfection 
using a Dual-Luciferase Reporter Assay System 
(Promega). Relative luciferase activity was calculated by 
normalizing to the renilla luminescence.
Clinical samples
Clinical FFPE (Formaldehyde Fixed Paraffin 
Embedded) samples of AfA (n = 81) and CaA (n = 51) 
and clinical information were obtained from the Urology 
Tissue Bank of the Veteran Affair Medical Center at San 
Francisco (VAMCSF; 40 AfA and 51 CaA FFPE samples) 
and National Disease Research Interchange (NDRI; 41 
AfA FFPE samples). The miRNeasy FFPE (Qiagen, 
Germany) was employed for isolation of RNA and cDNA 
was synthesized with a TaqMan MicroRNA Reverse 
Transcription Kit (ThermoFisher Scientific, MA) and 
checked by Taq-Man miRNA assays with Quant Studio 
7. The expression levels of miR-24 in PCa samples were 
compared with paired normal and normalized by Z-score. 
Statistical analysis for race-relationships between AfA and 
CaA were performed using Fisher’s exact test.
Immunohistochemistry
Immunohistochemical (IHC) staining was 
performed in 24 African-American and 11 Caucasian-
American prostate cancer specimens. Vision™ 
UltraVision™ Detection System (Thermo Scientific) was 
used to stain AR proteins. AR (Cell Signaling, 5153) 
diluted 1:400 in 5% normal goat serum in PBST. DAB 
substrate was incubate for 10 min. ImageJ calculated AR 
positive area. Threshold was set by 140.
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